Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01272076 · ClinicalTrials.gov registry record

Cirrus HD-OCT Measurement of Area of Increased Light Penetration Under the Retinal Pigment Epithelium (RPE)

A clinical trial of Age-related Macular Degeneration and Geographic Atrophy, sponsored by Carl Zeiss Meditec.

Completed
Registry status
85
Enrollment target
2
Study locations

NCT01272076: Completed study of Age-related Macular Degeneration and Geographic Atrophy, sponsored by Carl Zeiss Meditec.

NCT01272076 is a study of Age-related Macular Degeneration and Geographic Atrophy that has completed, run by Carl Zeiss Meditec. The registered enrollment target is 85 participants, below the 1,507-participant average among 74 other Age-related Macular Degeneration trials with a reported enrollment target (94% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01272076, a study of Age-related Macular Degeneration and Geographic Atrophy, has completed, sponsored by Carl Zeiss Meditec.

COMPLETED
Registry status
85 participants
Enrollment target
2
Study locations

Study Summary

The objective of this study is to compare Cirrus HD-OCT automated measurements of the illumination area under the retinal pigment epithelium (RPE) to expert manual measurements of areas of hypofluorescence typical of geographic atrophy in fundus autofluorescence (FAF) images.

Primary Outcome

In retinal areas with atrophy, light emitted from the Cirrus penetrates the sclera and choroid which are more reflecting compared with the Retinal Pigment Epithelium (RPE). The areas with higher illumination are associated with areas of Geographic Atrophy (GA), and allow to quantify how big is the area of atrophy. The study will assess the difference between Cirrus HD-OCT measurements of areas of increased illumination under the RPE to hypofluorescence areas on fundus photos as assessed manually

Study Locations (2)

California

  • East Bay Retina Consultants, Inc. - Oakland

Michigan

  • TLC Eyecare and Laser Centers - Jackson

Trial Details

FieldValue
Enrollment Target 85 participants
Start Date 2011-01
Est. Completion 2011-02
Carl Zeiss Meditec

18 total trials

What the finished NCT01272076 record still lists

NCT01272076 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 85 participants, a relatively small participant target, below the 1,507-participant average among 74 other Age-related Macular Degeneration trials with a reported enrollment target (94% lower).

The record links to 2 conditions, with Age-related Macular Degeneration appearing as the primary indexed condition, and to 0 interventions.

NCT01272076 reports a single indexed study location in California, Michigan.

Frequently Asked Questions

What is clinical trial NCT01272076 about?

NCT01272076 is a clinical study titled "Cirrus HD-OCT Measurement of Area of Increased Light Penetration Under the Retinal Pigment Epithelium (RPE)". The objective of this study is to compare Cirrus HD-OCT automated measurements of the illumination area under the retinal pigment epithelium (RPE) to expert manual measurements of areas of hypofluorescence typical of geographic atrophy in fundus autofluorescence (FAF) images.

What is the current status of trial NCT01272076?

This trial is currently completed. The enrollment target is 85 participants. The study started on 2011-01. Estimated completion is 2011-02.

What conditions does trial NCT01272076 study?

This clinical trial studies the following conditions: Age-related Macular Degeneration, Geographic Atrophy.

Who is sponsoring clinical trial NCT01272076?

This trial is sponsored by Carl Zeiss Meditec, which has 18 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01272076 being conducted?

This trial has 2 study locations across California, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Age-related Macular Degeneration

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01272076's enrollment target sits among peer trials

85 36th of 74 higher than 39 of 74 other Age-related Macular Degeneration trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Age-related Macular Degeneration trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00842283 · 85 participants

    Role of Angiogenesis in Dermatologic Diseases: A Potential Therapeutic Target

  • NCT02133196 · 85 participants · Phase 2

    T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer

  • NCT03823144 · 85 participants · NA

    Intravital Microscopy in Human Solid Tumors

  • NCT03875638 · 85 participants · Phase 2

    Treating Hyperexcitability in AD With Levetiracetam

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01272076, the US trial registry maintained by the National Library of Medicine. NCT01272076 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.